Prophylactic Para Aortic Irradiation vs Pelvic Radiotherapy in Pelvic node-positive Carcinoma Cervix in the setting of concurrent chemoradiation: A phase II Open-label Multi centric Randomized Controlled Trial (PRO-PARA)
Tapesh Bhattacharyya, View ORCID ProfileSantam Chakraborty, Bhavana Rai, Shirley Lewis, Srinivas Gowda, Anurupa Mahata, Samar Mandal, Gaurav Trivedi, Sreekripa Rao, Sarath Shyan
doi: https://doi.org/10.1101/2024.04.16.24305717
Tapesh Bhattacharyya
1Department of Radiation Oncology, Tata Medical Center, Kolkata
Santam Chakraborty
1Department of Radiation Oncology, Tata Medical Center, Kolkata
Bhavana Rai
2Department of Radiation Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh
Shirley Lewis
3Department of Radiation Oncology, Kasturba Medical College, Manipal
Srinivas Gowda
2Department of Radiation Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh
Anurupa Mahata
1Department of Radiation Oncology, Tata Medical Center, Kolkata
Samar Mandal
1Department of Radiation Oncology, Tata Medical Center, Kolkata
Gaurav Trivedi
2Department of Radiation Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh
Sreekripa Rao
3Department of Radiation Oncology, Kasturba Medical College, Manipal
Sarath Shyan
3Department of Radiation Oncology, Kasturba Medical College, Manipal
Article usage
Posted April 19, 2024.
Prophylactic Para Aortic Irradiation vs Pelvic Radiotherapy in Pelvic node-positive Carcinoma Cervix in the setting of concurrent chemoradiation: A phase II Open-label Multi centric Randomized Controlled Trial (PRO-PARA)
Tapesh Bhattacharyya, Santam Chakraborty, Bhavana Rai, Shirley Lewis, Srinivas Gowda, Anurupa Mahata, Samar Mandal, Gaurav Trivedi, Sreekripa Rao, Sarath Shyan
medRxiv 2024.04.16.24305717; doi: https://doi.org/10.1101/2024.04.16.24305717
Prophylactic Para Aortic Irradiation vs Pelvic Radiotherapy in Pelvic node-positive Carcinoma Cervix in the setting of concurrent chemoradiation: A phase II Open-label Multi centric Randomized Controlled Trial (PRO-PARA)
Tapesh Bhattacharyya, Santam Chakraborty, Bhavana Rai, Shirley Lewis, Srinivas Gowda, Anurupa Mahata, Samar Mandal, Gaurav Trivedi, Sreekripa Rao, Sarath Shyan
medRxiv 2024.04.16.24305717; doi: https://doi.org/10.1101/2024.04.16.24305717
Subject Area
Subject Areas
- Addiction Medicine (401)
- Allergy and Immunology (711)
- Anesthesia (204)
- Cardiovascular Medicine (2964)
- Dermatology (250)
- Emergency Medicine (443)
- Epidemiology (12774)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4605)
- Geriatric Medicine (422)
- Health Economics (732)
- Health Informatics (2938)
- Health Policy (1070)
- Hematology (390)
- HIV/AIDS (927)
- Medical Education (429)
- Medical Ethics (116)
- Nephrology (474)
- Neurology (4386)
- Nursing (237)
- Nutrition (643)
- Oncology (2282)
- Ophthalmology (649)
- Orthopedics (258)
- Otolaryngology (326)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1199)
- Primary Care Research (499)
- Public and Global Health (6973)
- Radiology and Imaging (1538)
- Respiratory Medicine (917)
- Rheumatology (442)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)